Journal article
Multicenter Open‐Label Sertraline Study in Adolescent Outpatients With Major Depression
Journal of the American Academy of Child and Adolescent Psychiatry, v 38(5), pp 566-572
1999
PMID: 10230188
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The aim of this multicenter outpatient study was to assess the therapeutic benefits, response patterns, and safety of sertraline in adolescent major depressive disorder (MDD).
Fifty-three adolescent outpatients with MDD were treated in an open-label, 10-week, acute-phase trial with sertraline and, if responders, for an additional 12-week continuation phase. Diagnostic and response assessments included the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), 17-item K-SADS-derived depression severity score, Hamilton Depression Rating Scale, Beck Depression Inventory, and Clinical Global Impression Scale.
By 2 weeks, when analyzed as continuous variables, all severity scores showed significant differences from baseline. This pattern persisted through 10 weeks, with a significantly greater response occurring when treatment was extended from 6 to 10 weeks. Both clinician- and patient-rated improvement was maintained during continuation treatment. Response rates varied considerably when depression rating scales were analyzed categorically. Sertraline was generally well tolerated and did not induce manic symptoms. Conclusions: In open treatment of adolescent MDD with sertraline, significant improvement occurred early on and was maintained for 22 weeks. Absolute response rates varied depending on the rating scales used, definition of response, and length of treatment. Maximal response rates were obtained by clinician-defined ratings after 10 weeks of treatment.
Metrics
Details
- Title
- Multicenter Open‐Label Sertraline Study in Adolescent Outpatients With Major Depression
- Creators
- PAUL J. Ambrosini - The University of Texas Medical Branch at GalvestonKAREN DINEEN Wagner - The University of Texas Medical Branch at GalvestonJOSEPH Biederman - The University of Texas Medical Branch at GalvestonIRA Glick - The University of Texas Medical Branch at GalvestonCLAIRE Tan - The University of Texas Medical Branch at GalvestonJOSEPHINE Elia - The University of Texas Medical Branch at GalvestonJOAN R. Hebeler - The University of Texas Medical Branch at GalvestonHARRIS Rabinovich - The University of Texas Medical Branch at GalvestonJAMES Lock - The University of Texas Medical Branch at GalvestonDANIEL Geller - The University of Texas Medical Branch at Galveston
- Publication Details
- Journal of the American Academy of Child and Adolescent Psychiatry, v 38(5), pp 566-572
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- [Retired Faculty]
- Web of Science ID
- WOS:000079956100018
- Scopus ID
- 2-s2.0-13044300889
- Other Identifier
- 991019167873604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Pediatrics
- Psychiatry
- Psychology, Developmental